Halozyme Therapeutics Inc (HALO)

[maumar]

Golden cross. Dips are being bought. It seems to me stock is performing well and the market thinks it's cheap.

I wouldn't be surprised if royalties doubled this quarter and I think they may double again the following quarter. The collaboration with Janssen further validates the Enhanze platform and makes it more likely that when Herceptin SC and Mabthers SC become obsolete they will be replaced by other drugs. Royalties will probably be at least $100M by 2017.

One more partnership or good news on PEG and the stock is likely to hit new highs rather quickly. Also, a Roche/FMI type of deal may happen any day, though I think KIrk/Torley/Frost will wait until 2017 and sell Halo for over $10B.

You may be right that "the stock is going down" but you are more likely to be wrong imho. There must be less risky stocks to short out there.